Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00007280
Other study ID # R01AR046557
Secondary ID R01AR046557NIAMS
Status Completed
Phase Phase 1
First received December 16, 2000
Last updated August 1, 2013
Start date October 2000
Est. completion date August 2005

Study information

Verified date April 2008
Source Roger Williams Medical Center
Contact n/a
Is FDA regulated No
Health authority United States: Federal Government
Study type Interventional

Clinical Trial Summary

This study will look at whether a graft of bioengineered skin (BSC), known commercially as Apligraf, stimulates the healing process in a person's own skin at the edge of a wound (known as the edge effect). The information from this study will provide a better understanding of the ways that grafts of bioengineered skin help the healing of chronic wounds.

We will assign study participants to either the bioengineered skin group or the control group. People in the control group will receive compression therapy with a multilayered compression bandage. We will examine each participant before starting treatment and then once a week for 24 weeks or until the wound heals. On the first day of treatment (day 0) and at week 3, week 6, and week 24 (end of treatment) we will take a small tissue sample from the wound for a biopsy. After the wound is completely healed, we will ask the patient to return once a month for 6 months to make sure the wound stays healed.


Description:

BSC is a two-layered sheet made from purified beef tendon collagen, living human cells, and a substance that maintains the cells until they are grafted (removed). We will obtain human cells from donors unrelated to the patient. The human cells have been tested for the presence of infectious agents and found to be free of disease-causing organisms such as hepatitis virus, the AIDS virus, bacteria, and fungi.

We will randomly assign (randomize) study participants to either the bioengineered skin group or control group (compression therapy with a multilayered compression bandage). Regardless of the group to which a patient is assigned, we expect participation in this study for 12 months following the start of study treatment. We will examine each patient at the screening visit (2 weeks before randomization) and then again 3-4 days before the start of treatment to make sure the wound is free of any signs of infection. After the initial randomization visit we will examine the wound once a week for 24 weeks or until the wound heals, whichever is earlier. As soon as we have determined that the wound is completely healed, we will ask the patient to return once a month for 6 months to make sure it remains healed.

Bioengineered skin group: We will apply BSC to the wound and cover it with xeroform dressing, foam bolster, gauze dressing, and compression bandage. If we do not note any improvement at the week 6 visit, we will apply BSC on the wound a second time.

Control group: We will place a multilayered compression bandage on the wound of participants assigned to this group.

Biopsies (small piece of skin tissue): At day 0 a biopsy will be taken from the thigh and leg ulcer. The biopsy from the thigh will require sutures and will be removed in ten days. Sometime between weeks 1 and 3, week 6, week 24 and week 48 (6 month follow-up) visits a biopsy will be taken from the ulcer (wound) if the ulcer has not healed. If the ulcer is healed at the week 48 visit, a light scraping of the healed wound will be performed.

Study examinations: All study examinations will include observation, measurement, and photography.

We can only admit women of childbearing age to the study if they are not breast feeding, not pregnant, or have been surgically sterilized or are using effective birth control. Because the effects of the proposed treatments on a fetus are unknown, we will remove from the study any woman who becomes pregnant while receiving BSC applications (day 0-week 3) and suggest another method of treatment.


Recruitment information / eligibility

Status Completed
Enrollment 50
Est. completion date August 2005
Est. primary completion date August 2005
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Men or women at least 18 years old

- At least one ulcer (wound) greater than or equal to 2 centimeters

- Ulcer (wound) present for at least 3 months or greater

- Ankle/brachial index > 0.7

- Patient must be ambulatory

- Patient must read, understand and sign informed consent

Exclusion Criteria:

- Medical conditions limiting participation

- History of poor compliance, unreliability

- History of allergy to bovine collagen

- Gangrene, vasculitis, collagen vascular disease osteomyelitis or exposed tendons

- Use of systemic steroids/immunosuppressives

- History of diabetes mellitus

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Device:
Bioengineered skin


Locations

Country Name City State
United States Roger Williams Medical Center Dept. of Dermatology & Skin Surgery Providence Rhode Island

Sponsors (2)

Lead Sponsor Collaborator
Roger Williams Medical Center National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

Country where clinical trial is conducted

United States, 

References & Publications (11)

Badiavas EV, Falanga V. Treatment of chronic wounds with bone marrow-derived cells. Arch Dermatol. 2003 Apr;139(4):510-6. — View Citation

Brem H, Kirsner RS, Falanga V. Protocol for the successful treatment of venous ulcers. Am J Surg. 2004 Jul;188(1A Suppl):1-8. Review. — View Citation

Butmarc J, Yufit T, Carson P, Falanga V. Human beta-defensin-2 expression is increased in chronic wounds. Wound Repair Regen. 2004 Jul-Aug;12(4):439-43. — View Citation

Falanga V, Isaacs C, Paquette D, Downing G, Kouttab N, Butmarc J, Badiavas E, Hardin-Young J. Wounding of bioengineered skin: cellular and molecular aspects after injury. J Invest Dermatol. 2002 Sep;119(3):653-60. — View Citation

Falanga V, Sabolinski M. A bilayered living skin construct (APLIGRAF) accelerates complete closure of hard-to-heal venous ulcers. Wound Repair Regen. 1999 Jul-Aug;7(4):201-7. — View Citation

Kim BC, Kim HT, Park SH, Cha JS, Yufit T, Kim SJ, Falanga V. Fibroblasts from chronic wounds show altered TGF-beta-signaling and decreased TGF-beta Type II receptor expression. J Cell Physiol. 2003 Jun;195(3):331-6. — View Citation

Nahm WK, Philpot BD, Adams MM, Badiavas EV, Zhou LH, Butmarc J, Bear MF, Falanga V. Significance of N-methyl-D-aspartate (NMDA) receptor-mediated signaling in human keratinocytes. J Cell Physiol. 2004 Aug;200(2):309-17. — View Citation

Nahm WK, Zhou L, Falanga V. Sustained ability for fibroblast outgrowth from stored neonatal foreskin: a model for studying mechanisms of fibroblast outgrowth. J Dermatol Sci. 2002 Feb;28(2):152-8. — View Citation

Phillips TJ, Manzoor J, Rojas A, Isaacs C, Carson P, Sabolinski M, Young J, Falanga V. The longevity of a bilayered skin substitute after application to venous ulcers. Arch Dermatol. 2002 Aug;138(8):1079-81. — View Citation

Saap LJ, Donohue K, Falanga V. Clinical classification of bioengineered skin use and its correlation with healing of diabetic and venous ulcers. Dermatol Surg. 2004 Aug;30(8):1095-100. — View Citation

Shen JT, Falanga V. Growth factors, signal transduction, and cellular responses. J Dermatol. 2003 Jan;30(1):5-16. Review. — View Citation

* Note: There are 11 references in allClick here to view all references

Outcome

Type Measure Description Time frame Safety issue
Primary Measurement and characterization of stimulation of the wound's edges treated with the bioengineered skin construct (BSC) Measured throughout the study till Week 48 No
Secondary Response of BSC to injury, including meshed (wounded) and unmeshed BSC Measured throughout the study till Week 48 No
Secondary Activation of certain critical cytokines, including IL-1 alpha, IL-6, and TGF-beta Measured throughout the study till Week 48 No
See also
  Status Clinical Trial Phase
Terminated NCT00762138 - The AutoloGelâ„¢ Post-Market Surveillance (TAPS) Program N/A
Recruiting NCT02583958 - Assessment of Efficacy & Safety for a New Wound Dressing Urgo 310 3166 in the Local Treatment of VLU or Mixed Leg Ulcers N/A
Completed NCT01238419 - Physiotulle vs Urgotul in the Treatment of Leg Ulcer Phase 4
Active, not recruiting NCT05561140 - Resolution of Sickle Cell Leg Ulcers With Voxelotor Phase 3
Completed NCT00710489 - Potential Research Study Participant Registry
Completed NCT00628004 - Safety Evaluation of Biatain Ibu in Painful Chronic Venous Leg Ulcers N/A
Completed NCT00821431 - Compression Device Versus 4-layer Compression System Phase 2
Not yet recruiting NCT00922389 - A Clinical Trial on Diabetic Foot Using Peripheral Blood Derived Stem Cells for Treating Critical Limb Ischemia Phase 1/Phase 2
Completed NCT00184873 - Legtest Multi Centre Testing of the Lively Legs Program for Promoting Compliance in Leg Ulcer Patients N/A
Completed NCT00807664 - Biatain Ag vs Biatain in the Treament of Leg Ulcers N/A
Completed NCT01427491 - Compare Aquacel® Ag Versus Mepilex® Border Ag to Manage Bioburden in Leg Ulcers Phase 3
Completed NCT00522002 - CLUE Study: Connective Tissue Disease Leg Ulcer Etiology Study N/A
Completed NCT02632695 - Physical Activity Interventions for Leg Ulcer Patients N/A